|
|
Office Locations:
|
200 Crescent Court, Suite 1600
Dallas, TX 75201
| |
|
|
|
|
|
|
Business Services
Consumer Products & Services
Life Sciences & Healthcare
Manufacturing & Industrial
|
|
|
|
Prolign makes equity investments in lower middle market companies alongside Independent Sponsors and management teams. During the life of these investments, Prolign supports and collaborates with its Independent Sponsor partners and management teams to execute on multi-faceted value creation plans that foster growth, enhance operations, and generate superior returns for all shareholders. Prolign targets firms with EBITDA of $5.0 million or greater, EBITDA margins greater than 10%; with a $10 to $25 million target investment size. Prolign focuses on companies headquartered in the U.S. or Canada with primary operations in North America. Prolign will selectively consider small debt investments alongside an equity investment. Preferred industries include: Commercial and professional services; Industrial services; Value-added manufacturing; Healthcare services and equipment; Consumer durables; Consumer services; Building products and services. Prolign does not invest in real estate ventures, oil and gas exploration, highly regulated industries, and turnaround situations
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
